|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We semiquantitatively measured nuclear expression of karyopherin a2 and the MIB1 labeling index, by immunohistochemical analysis, for 94 primary (23 astrocytomas WHO grade II, 24 astrocytomas WHO grade III, 47 glioblastomas) and 12 recurrent gliomas.
|
22772608 |
2012 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are no known molecules that are directly linked to the MIB-1 LI in astrocytomas.
|
19937366 |
2010 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aims of the research reported here were (1) to evaluate the Cx43 protein and mRNA of both low histological grade and high histological grade astrocyte tumors; (2) to evaluate if the immunohistochemistry of the Cx43 protein in astrocytomas could be correlated to histological grade, to proliferative activity (Ki67/Mib1-index) and to immunolabelling of the epidermal growth factor receptor (EGFR); (3) to evaluate if the reduction in levels of the Cx43 protein correlates with reduction in levels of the Cx43 mRNA.
|
19604543 |
2010 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The markers p53 and MIB-1 were significantly higher expressed in astrocytomas than in oligodendrogliomas and expression levels of p53 and EGFR were inversely associated within the astrocytic group.
|
17390041 |
2007 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The studies reviewed report MIB-1 LI as an important prognostic factor in human astrocytomas.
|
16998593 |
2006 |
|
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Astrocytomas with a gemistocytic component (AG) are similar to A with respect to survival and MIB-LI and TUNEL-LI.
|
10720205 |
1999 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlative analyses of IGF-1, p53, and Ki-67 (MIB-1) immunohistochemistry and IGF-1 receptor (IGF-1R) mRNA expression were performed to examine the cellular pattern of IGF-1 signaling in 39 cases of astrocytoma (World Health Organization grades II-IV).
|
11550306 |
1999 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low CDKN2/p16 expression was also associated with high cell proliferation activity (MIB-1 immunocytochemistry: p = 0.004; mitotic index: p = 0.007) and poor patient survival (p = 0.025) in astrocytomas.
|
10359140 |
1999 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, MIB-1 or p53 staining alone cannot differentiate pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas.
|
9839169 |
1998 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis was restricted to the group of diffuse astrocytomas (48 patients). pRb expression did not correlate with histological type, grade or p53 expression, while a moderately strong correlation existed between pRb expression and the percentages of proliferating cell nuclear antigen (PCNA) and MIB-1-positive cells.
|
9650754 |
1998 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the role of gemistocytes in astrocytoma progression, we assessed the fraction of neoplastic gemistocytes, bcl-2 expression, p53 mutations, p53 immunoreactivity (PAb 1801), and proliferative activity (MIB-1) in 40 low-grade astrocytomas (World Health Organization (WHO) Grade II) with histologically proven progression to anaplastic astrocytoma (WHC Grade III) or glioblastoma (WHO Grade IV).
|
9042164 |
1997 |